bioAffinity Technologies Joins National Lung Cancer Roundtable
October 11, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer...
bioAffinity Technologies Announces Members of its Scientific and Medical Advisory Board
October 02, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced the members of its Scientific and Medical Advisory (SMA) Board who will...
bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair
March 12, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 12, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide...
bioAffinity Technologies Selected as Finalist for Cancer Innovation Award
March 06, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 06, 2019 (GLOBE NEWSWIRE) -- Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics...
bioAffinity Technologies Announces Award of Canadian Patent
February 04, 2019 12:25 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the...
South Texas Veterans Health Care System Joins Test Validation Trial of bioAffinity’s CyPath® Lung
October 23, 2018 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is...
bioAffinity Licenses CyPath® Lung to Precision Pathology Services
October 10, 2018 12:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued...
Mount Sinai Joins Test Validation Trial of bioAffinity’s CyPath® Lung
September 18, 2018 14:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY,...
bioAffinity Technologies Welcomes Mohsin Y. Meghji to Board of Directors
July 31, 2018 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 31, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin...
bioAffinity Technologies Opens Test Validation Trial of CyPath® Lung
July 17, 2018 14:40 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 17, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an...